Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

Hyangin Kim, … , Yinghong Tian, Jianren Mao


Pain and depression are frequently comorbid disorders, but the mechanism underlying this association is unknown. Here, we report that brain indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting enzyme in tryptophan metabolism, plays a key role in this comorbidity. We found that chronic pain in rats induced depressive behavior and IDO1 upregulation in the bilateral hippocampus. Upregulation of IDO1 resulted in the increased kynurenine/tryptophan ratio and decreased serotonin/tryptophan ratio in the bilateral hippocampus. We observed elevated plasma IDO activity in patients with both pain and depression, as well as in rats with anhedonia induced by chronic social stress. Intra-hippocampal administration of IL-6 in rats, in addition to in vitro experiments, demonstrated that IL-6 induces IDO1 expression through the JAK/STAT pathway. Further, either Ido1 gene knockout or pharmacological inhibition of hippocampal IDO1 activity attenuated both nociceptive and depressive behavior. These results reveal an IDO1-mediated regulatory mechanism underlying the comorbidity of pain and depression and suggest a new strategy for the concurrent treatment of both conditions via modulation of brain IDO1 activity.

Find the latest version:
http://jci.me/61884-pdf
Pain and depression are frequently comorbid disorders, but the mechanism underlying this association is unknown. Here, we report that brain indoleamine 2,3-dioxygenase 1 (IDO1), a rate-limiting enzyme in tryptophan metabolism, plays a key role in this comorbidity. We found that chronic pain in rats induced depressive behavior and IDO1 upregulation in the bilateral hippocampus. Upregulation of IDO1 resulted in the increased kynurenine/tryptophan ratio and decreased serotonin/tryptophan ratio in the bilateral hippocampus. We observed elevated plasma IDO activity in patients with both pain and depression, as well as in rats with anhedonia induced by chronic social stress. Intra-hippocampal administration of IL-6 in rats, in addition to in vitro experiments, demonstrated that IL-6 induces IDO1 expression through the JAK/STAT pathway. Further, either Ido1 gene knockout or pharmacological inhibition of hippocampal IDO1 activity attenuated both nociceptive and depressive behavior. These results reveal an IDO1-mediated regulatory mechanism underlying the comorbidity of pain and depression and suggest a new strategy for the concurrent treatment of both conditions via modulation of brain IDO1 activity.

Introduction

Pain and depression often coexist in the clinical setting, which complicates the treatment of both conditions. The prevalence rate of depression is several times higher in patients with chronic pain than in the general population (1), whereas depression significantly increases the risk of developing chronic pain (2). Currently, antidepressants and analgesics are often prescribed in combination for symptomatic management, but this clinical approach has achieved only limited success (3). To date, the cellular mechanism underlying the comorbid relationship between pain and depression remains unclear.

Tryptophan is an essential amino acid and the precursor of serotonin and kynurenine, two neuromodulators critically implicated in the regulation of neuronal excitation (4) and depression (5). Indoleamine 2,3-dioxygenase 1 (IDO1) is a rate-limiting enzyme in tryptophan metabolism. Relative to its basal expression in immune cells, IDO1 is significantly upregulated in response to inflammation (5, 6). Recent studies in the depression and immunology fields have shown that IDO1 activity is linked to (a) decreased serotonin content (1) and depression (1, 5) and (b) increased kynurenine content and neuroplastic changes through the effect of its derivatives such as quinolinic acid on glutamate receptors (7). Moreover, IDO1 expression has been shown to be induced by proinflammatory cytokines, leading to the increased kynurenine production (8–10).

Since proinflammatory cytokines including IL-6 have been implicated in the pathophysiology of both pain (11) and depression (12), it is possible that regulation of brain IDO1 by proinflammatory cytokines could serve as a critical mechanistic link in the comorbid relationship between pain and depression through the regulation of tryptophan metabolism. We tested this hypothesis by utilizing a rat model of induced depressive behavior resulting from persistent hind paw inflammatory pain (13).

Results

Persistent nociception induces depressive behavior. Inflammatory arthritis in Wistar rats induced by the injection of CFA into the right tibiotarsal joint produced mechanical allodynia (Figure 1A; ANOVA, F(3,104) = 3.11, P < 0.05) and thermal hyperalgesia (Figure 1B; F(3,121) = 8.99, P < 0.05), which lasted for at least 21 days as compared with sham control rats injected with incomplete Freund’s adjuvant. This condition of persistent nociception induced depressive behavior in these same rats when examined on days 7 and 14, but not on day 1, in the forced swimming test (FST) (ref. 14 and Figure 1C; F(3,37) = 18.91; P < 0.01) and open field test (OFT) (refs. 15, 16, and Figure 1D; F(3,31) = 6.08, P < 0.05). A shorter hind paw withdrawal latency in arthritic rats correlated with a longer immobility time in FST (Figure 1E) and a lower frequency in OFT (Figure 1F), demonstrating a comorbid relationship between pain and depression in these rats. Of note, the increased immobility time in FST and reduced frequency in OFT were observed in both arthritic and sham control rats on day 1 but only in arthritic rats on day 7 and day 14. Testing of depressive behavior was not extended beyond day 14 in order to avoid habituation to the testing environment, because there were no differences after day 14 in nociceptive behavior. The intensity of exploratory behavior (e.g., rearing and crossing in OFT) was similar in arthritic and sham control rats, although arthritic rats had a lower frequency of exploratory behaviors. Moreover, there were no differences in a rotarod test between rats with or without hind paw arthritis on day 7 (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI61884DS1), suggesting that the observed depressive behavior was unlikely due to changes in motor function.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2012;122(8):2940–2954. doi:10.1172/JCI61884.
Hippocampal IDO1 expression is upregulated in rats with coexistent nociceptive and depressive behavior. We first examined whether brain IDO1 expression (hippocampus, thalamus, and nucleus accumbens) would differ in rats with or without coexistent nociceptive and depressive behavior. IDO1 immunoreactivity in the hippocampus (Figure 2A) was co-localized with glial fibrillary acidic protein (GFAP; astrocyte marker), Iba-1 (microglial marker), and NeuN (neuronal marker) (Figure 2B), consistent with both in vivo and in vitro expression of IDO1 in immune cells and neurons (17, 18). While the basal Ido1 mRNA level (real-time PCR) in the bilateral hippocampus was similar in arthritic and sham rats (naive, day 0; contralateral side only), the Ido1 mRNA level was progressively increased on days 1, 7, and 14 in arthritic but not sham rats (Figure 2C; \( P < 0.05 \)). The IDO1 protein level (Western blot analysis) was also elevated in the hippocampus (Figure 2D; contralateral side only, \( P < 0.05 \)), but not in the thalamus or nucleus accumbens (Figure 2, E and F), of arthritic rats. Moreover, there was a temporal relationship between IDO1 upregulation and nociceptive (Figure 1, A and B) and depressive behavior (Figure 1, C and E) in these same rats.

Increased IDO1 enzyme activity alters ratios of hippocampal tryptophan metabolites. To examine the role of IDO1 enzyme activity in tryptophan metabolism in both arthritic and sham rats, we first measured the content of tryptophan, serotonin, and kynurenine in the hippocampus using HPLC and then determined the ratio of serotonin or kynurenine to tryptophan. There were no baseline differences in the kynurenine/tryptophan or serotonin/tryptophan ratio between arthritic and sham control rats (Figure 3, A and B). However, the kynurenine/tryptophan ratio was significantly increased (Figure 3A; \( P < 0.05 \)), while the serotonin/tryptophan ratio was decreased (Figure 3B; \( P < 0.05 \)), in arthritic rats as compared with sham control rats when measured on both day 1 and day 14. In contrast, IDO1 enzyme activity (both kynurenine/tryptophan and serotonin/tryptophan ratios) was not changed in the thalamus of arthritic rats (Figure 3, C and D). In addition, the plasma kynurenine/tryptophan ratio was also significantly increased (Figure 3E; \( P < 0.05 \)) in arthritic rats as compared with sham control rats when measured on day 14. Consistent with the IDO1 upregulation in arthritic rats, altered ratios of tryptophan metabolites in the hippocampus indicate increased IDO1 enzyme activity in rats with coexistent nociceptive and depressive behavior.

Patients with both chronic back pain and depression also showed a significantly elevated plasma IDO1 level (Figure 3G) and increased IDO1 enzyme activity (Figure 3H; increased kynurenine/tryptophan ratio) as compared with healthy control subjects without pain and depression (\( P < 0.05 \)). In contrast, the serotonin/tryptophan ratio was not different between.
healthy control subjects and patients with both pain and depression (Figure 3I). Although the data were obtained in a cross-sectional observational setting, these findings suggest that a relationship could also exist in human subjects between IDO1 activity and combined pain and depression.

Presence of anhedonic behavior exacerbates nociceptive behavior. In order to examine the generality of hippocampal IDO1 expression in relation to the interaction between nociception and depression, we used an established rat model of anhedonia induced by chronic social stress (see Methods). After 2 weeks of chronic social stress, rats

Figure 2
IDO1 expression in the hippocampus. (A) IDO1 immunoreactivity was detected in the hippocampus. Scale bars: 1.0 mm (top), 50 μm (bottom). (B) Photomicrographs of colocalization between IDO1 and GFAP, Iba-1, or NeuN in the hippocampus. Scale bars: 50 μm. (C and D) Ido1 mRNA (C) and protein (D) expression was increased in the contralateral hippocampus of Wistar rats injected with CFA as detected by real-time PCR (C) and Western blot analysis (D). Day 0, baseline (naive rats); C-1 and C-14, samples taken on day 1 and day 14 from rats with CFA-induced arthritis; S-1 and S-14, samples taken on day 1 and day 14 from sham control rats. β-Actin was used as loading control. y axis shows fold change in IDO1 mRNA and protein expression. Mean ± SEM, n = 6–10, *P < 0.05 compared with sham control. (E and F) IDO1 expression (Western blot) was not upregulated in the thalamus (E) or nucleus accumbens (F) in Wistar rats with CFA-induced arthritis; n = 6, P > 0.05.
demonstrated a significant decrease in body weight gain and sucrose preference relative to control rats without social stress (Figure 4A, $F(1,23) = 438.20, P < 0.05$; Figure 4B, $F(1,23) = 172.12, P < 0.05$), indicating the presence of anhedonic behavior. These rats also exhibited other depressive behaviors, manifesting as a longer immobility time in both FST (Figure 4C; $F(2, 35) = 31.86, P < 0.05$) and tail suspension test (TST) (Figure 4D; $F(2,35) = 369.08, P < 0.05$). Moreover, these same rats exhibited a progressively lower baseline nociceptive threshold in response to mechanical (Figure 4E; $F(1,23) = 312.85, P < 0.05$) and thermal stimulation (Figure 4F; $F(1,23) = 100.276, P < 0.05$) during 3 weeks of chronic social stress, indicating that the presence of anhedonic behavior also influenced baseline nociceptive response.

To examine whether preexisting anhedonic behavior would exacerbate nociceptive behavior following hind paw arthritis, we exposed anhedonic and control rats, following 3 weeks of social stress and sham control respectively, to either CFA hind paw arthritis or sham control and examined behavioral changes 1 week later. Both mechanical allodynia (Figure 4G; $F(4,35) = 164.98, P < 0.05$) and thermal hyperalgesia (Figure 4H; $F(4,35) = 63.72, P < 0.05$) were exacerbated in anhedonic rats as compared with control rats, associated with a significantly longer immobility time in FST (Figure 4I; $F(4,33) = 63.19, P < 0.05$) and TST (Figure 4J; $F(4,33) = 73.74, P < 0.05$) in these same rats. Moreover, the IDO1 expression (Western blot) in the bilateral hippocampus was significantly increased in anhedonic rats as compared with control rats, associated with a significantly longer immobility time in FST (Figure 4I; $F(4,33) = 63.19, P < 0.05$) and TST (Figure 4J; $F(4,33) = 73.74, P < 0.05$) in these same rats. Moreover, the IDO1 expression (Western blot) in the bilateral hippocampus was significantly increased in anhedonic rats as compared with control rats, associated with a significantly longer immobility time in FST (Figure 4I; $F(4,33) = 63.19, P < 0.05$) and TST (Figure 4J; $F(4,33) = 73.74, P < 0.05$) in these same rats. Moreover, the IDO1 expression (Western blot) in the bilateral hippocampus was significantly increased in anhedonic rats as compared with control rats, associated with a significantly longer immobility time in FST (Figure 4I; $F(4,33) = 63.19, P < 0.05$) and TST (Figure 4J; $F(4,33) = 73.74, P < 0.05$) in these same rats.
Inhibition of IDO1 activity concurrently attenuates nociceptive and depressive behavior. To examine whether inhibition of IDO1 activity would influence nociceptive and depressive behaviors in arthritic rats, we administered the IDO1 inhibitor L-1-methyl-tryptophan (1-MT; 10 mg/d) (19) or vehicle intraperitoneally twice daily for 14 consecutive days. Treatment with 1-MT, but not vehicle, significantly attenuated both nociceptive (Figure 5A; $F(3,119) = 11.33; P < 0.05$) and depressive (Figure 5B; $F(3,63) = 5.54; P < 0.05$) behaviors in arthritic rats. Systemic 1-MT treatment alone did not alter behaviors in sham control rats (Figure 5, A and B), nor did it change the appearance of arthritic hind paw (e.g., redness or swelling).

To examine the brain site of 1-MT action, we microinjected 1-MT (5 μg in 0.5 μl volume, once daily for 7 days) into the hippocampus contralateral to the arthritic hind paw. Intra-hippocampal 1-MT treatment also (a) downregulated IDO1 expression (Figure 5E; $F(3,71) = 5.54, P < 0.05$) and depressive (Figure 5D; $F(3,31) = 14.70, P < 0.05$) behaviors in arthritic rats without changing behaviors in sham control rats, indicating that the hippocampus is a critical brain locus of IDO1 activity. The procedure of brain cannula implantation itself, used for intra-hippocampal microinjection, did not alter the baseline behavioral response when examined 5 days after the surgery (Supplementary Figure 1, B–D).

Intraperitoneal 1-MT treatment also attenuated both nociceptive (Figure 5C; $F(3,71) = 5.54, P < 0.05$) and depressive (Figure 5D; $F(3,31) = 14.70, P < 0.05$) behaviors in arthritic rats without changing behaviors in sham control rats, indicating that the hippocampus is a critical brain locus of IDO1 activity. The procedure of brain cannula implantation itself, used for intra-hippocampal microinjection, did not alter the baseline behavioral response when examined 5 days after the surgery (Supplementary Figure 1, B–D).

Intra-hippocampal 1-MT treatment also attenuated both nociceptive and depressive behaviors in arthritic rats, with and without CFA injection. Data in G–K are mean ± SEM, n = 6, $*P < 0.05$ compared with sham control. N, naive.
depressive behavior by the 1-MT treatment was mediated by the regulation of hippocampal IDO1 activity, thereby normalizing the content of tryptophan metabolites in the hippocampus.

Ido1 gene knockout attenuates both nociceptive and depressive behavior. To further confirm the role of IDO1 in the behavioral manifestation of pain and depression, we used IDO1-knockout and matched wild-type mice under the same experimental condition as that for Wistar rats. Both basal and arthritis-induced IDO1 expression in the hippocampus, as observed in age-matched wild-type mice, was absent in IDO1-knockout mice (Figure 6A). There were no baseline differences in behavioral tests for nociception (Figure 6, B and C; day 0) and depression (Figure 6, D and E; day 0) between IDO1-knockout and wild-type mice (each \( P > 0.05 \)). In IDO1-knockout mice, however, both mechanical allodynia (Figure 6B; \( F(3,120) = 9.86, P < 0.01 \)) and thermal hyperalgesia (Figure 6C; \( F(3,122) = 5.73, P < 0.05 \)) were significantly attenuated as compared with wild-type mice after the CFA injection into the right tibiotarsal joint. In these same knockout mice, the immobility time (FST) was not increased, nor was there a decrease in the frequency in OFT (Figure 6D; \( F(3,49) = 32.175, each P < 0.05 \)). These results indicate that Ido1 gene knockout concurrently attenuated nociceptive and depressive behavior induced by persistent hind paw nociception.

To examine whether selective reduction of nociceptive behavior would influence depressive behavior and hippocampal IDO1 expression, was given acetaminophen (N-acetyl-para-aminophen-
nol, 100 mg/kg) (20, 21), an analgesic agent without the anti-inflammatory effect, or vehicle once intraperitoneally on day 14 to arthritic or sham rats. When examined at 1 hour after the treatment, acetaminophen, but not vehicle, significantly reduced mechanical allodynia (Figure 6F; \( F(3,23) = 128.80, P < 0.05 \)) and thermal hyperalgesia (Figure 6G; \( F(3,23) = 839.97, P < 0.05 \)). The acetaminophen treatment did not acutely reverse depressive behavior (Figure 6H; FST), nor did it alter the \( \text{Il6} \) mRNA level in the same arthritic rats (Figure 6I). These results indicate that the correlation between nociception and depression demonstrated in these rats was not a simple coincidence but rather that the two were linked by the hippocampal IDO1 expression.

**IL-6 and JAK/STAT are increased in rats with nociceptive and depressive behavior.** Proinflammatory cytokines including IL-6 have been shown to be involved in the cellular mechanisms of both pain and depression (11, 12, 22). To examine the hypothesis that proinflammatory cytokines such as IL-6 and one of its downstream signaling pathways (JAK and STAT) (23, 24) would mediate hippocampal IDO1 upregulation, we first examined whether the IL-6 level and JAK/STAT expression would be increased in rats with coexistent nociceptive and depressive behavior. Both the plasma IL-6 level and hippocampal \( \text{Il6} \) mRNA expression were significantly increased in rats with nociceptive and depressive behavior as compared with sham rats (Figure 7, A and B; \( P < 0.05 \)). The hippocampal \( \text{Il6} \) mRNA

---

**Figure 6**

Effect of IDO-knockout on behavioral changes. (A) IDO-knockout mice had no \( \text{Ido1} \) mRNA expression (real-time PCR) in the hippocampus. \( \text{Ido1} \) mRNA expression in wild-type mice was increased in the hippocampus after the CFA injection. Mean ± SEM, \( n = 6, \ast P < 0.05 \) compared with sham control. (B and C) Mechanical allodynia (B) and thermal hyperalgesia (C) on the ipsilateral hind paw were attenuated in IDO-knockout mice. (D and E) IDO-knockout also reduced the immobility time in FST (D) and the decreased frequency in OFT (E) in the same mice with CFA-induced arthritis. Mean ± SEM, \( n = 6, \ast P < 0.05 \) compared with wild-type mice. (F and G) Intraperitoneal injection of acetaminophen (APAP; 100 mg/kg), given once on day 14, attenuated ipsilateral mechanical allodynia (F) and thermal hyperalgesia (G) when mice were examined at 1 hour after the injection. Mean ± SEM, \( n = 6, \ast P < 0.05 \) compared with vehicle control. (H) The same APAP treatment did not change the immobility time in FST in the same rats. (I) Contralateral hippocampal \( \text{Ido1} \) mRNA expression was increased after the CFA injection, which was not reversed by a single APAP treatment. Data in H and I are mean ± SEM, \( n = 6, \ast P < 0.05 \) compared with vehicle control.
The plasma IL-6 concentration was increased (A, ELISA), as was Il6 mRNA expression in the hippocampus (B, real-time PCR), in rats with CFA-induced arthritis. (C) Il6 mRNA expression was also increased in the hippocampus of both IDO-knockout and wild-type mice with CFA-induced arthritis. Mean ± SEM, n = 6, *P < 0.05 compared with sham control. (D) The plasma IL-6 level was elevated in patients with both back chronic pain and depression (ELISA). Mean ± SEM, n = 13–20, *P < 0.05 compared with healthy control. (E–G) The expression of JAK2 (E), STAT3 (F), and p-STAT3 (G) in the hippocampus was increased in rats with CFA-induced arthritis (Western blot analysis). C-1, C-7, and C-14, samples taken on days 1, 7, and 14 from rats with CFA-induced arthritis; S-1, S-7, and S-14, samples taken on days 1, 7, and 14 from sham control rats. β-Actin was used as loading control. Mean ± SEM, n = 4–5, *P < 0.05 compared with sham control.

**Figure 7** Role of IL-6 in the hippocampal JAK/STAT pathway. (A and B) The plasma IL-6 concentration was increased (A, ELISA), as was Il6 mRNA expression in the hippocampus (B, real-time PCR), in rats with CFA-induced arthritis. (C) Il6 mRNA expression was also increased in the hippocampus of both IDO-knockout and wild-type mice with CFA-induced arthritis. Mean ± SEM, n = 6, *P < 0.05 compared with sham control. (D) The plasma IL-6 level was elevated in patients with both chronic back pain and depression (ELISA). Mean ± SEM, n = 13–20, *P < 0.05 compared with healthy control. (E–G) The expression of JAK2 (E), STAT3 (F), and p-STAT3 (G) in the hippocampus was increased in rats with CFA-induced arthritis (Western blot analysis). C-1, C-7, and C-14, samples taken on days 1, 7, and 14 from rats with CFA-induced arthritis; S-1, S-7, and S-14, samples taken on days 1, 7, and 14 from sham control rats. β-Actin was used as loading control. Mean ± SEM, n = 4–5, *P < 0.05 compared with sham control.

Furthermore, we used a hippocampal organotypic slice culture taken from postnatal rats to examine the in vitro effect of IL-6 on hippocampal IDO1 expression and activity. After being cultured for 1 week, hippocampal slices were treated with IL-6 (100 ng/ml) or vehicle (PBS) for 24 hours. Exposure of exogenous IL-6, but not vehicle, increased Ido1 mRNA (real-time PCR, Figure 8F) and protein (Western blot analysis, Figure 8H; P < 0.05) in cultured slices. Under the same experimental condition, the kynurenine/tryptophan ratio was significantly increased, whereas the serotonin/tryptophan ratio was decreased in the culture medium (HPLC, Figure 8I; P < 0.05). Collectively, the results indicate that IL-6 has a direct cellular effect on IDO1 expression in the hippocampus.

IL-6–mediated hippocampal IDO1 expression concurrently regulates nociceptive and depressive behavior. To examine the functional role of IL-6 signaling in hippocampal IDO1 expression as well as its contribution to both nociceptive and depressive behavior, we microinjected an IL-6 antiserum into the hippocampus of arthritic or sham control rats. Microinjection of IL-6 antiserum (0.5 μg, once daily for 7 days) (22), but not control serum (vehicle), into the hippocampus contralateral to arthritic hind paw significantly attenuated mechanical allodynia (Figure 9A; F(1,39) = 9.28, P < 0.05), thermal hyperalgesia (Figure 9B; F(1,39) = 7.46,
P < 0.05), and depressive behavior (Figure 9C; $F(3,19) = 155.99$, $P < 0.001$). The same IL-6 antiserum treatment also prevented IDO1 upregulation in the hippocampus (Figure 9D; $P < 0.05$), consistent with the in vitro results of IL-6–induced IDO1 expression (Figure 8, B and C).

Conversely, microinjection of exogenous IL-6 (recombinant rat IL-6, 0.1 μg, once daily for 7 days) (25), but not vehicle, into the left hippocampus of naive rats (without arthritis) induced right hind paw mechanical allodynia (Figure 9E: $F(3,79) = 2.54$, $P < 0.05$) and thermal hyperalgesia (Figure 9F: $F(3,103) = 11.24$, $P < 0.01$), as well as depressive behavior (Figure 9G: $F(3,19) = 65.20$, $P < 0.001$) and increased Ido1 mRNA expression in the hippocampus (Figure 9H; $P < 0.05$). These IL-6 effects were prevented when IL-6 was co-administered with the JAK/STAT inhibitor AG490 (5 μg, once daily for 7 days) (26) into the hippocampus (Figure 9, E–H; each $P < 0.05$). Intra-hippocampal microinjection of AG490 alone had no effect on the baseline behavioral response and Ido1 mRNA expression in naive rats (Figure 9, E–H; each $P > 0.05$).

Taken together with the data obtained using the IDO1 inhibitor 1-MT, these findings indicate that the hippocampus is a central site of IL-6–regulated IDO1 expression critically contributory to the comorbid interaction between pain and depression.
Discussion

We have demonstrated that IDO1 expression was selectively upregulated in the hippocampus of Wistar rats with coexistent nociceptive and depressive behavior. The IDO1 level was also elevated in patients with both pain and depression. Either Ido1 gene knockout or inhibition of IDO1 activity, but not a transient reversal of nociceptive behavior alone by acetaminophen, concurrently attenuated nociceptive and depressive behavior. At the cellular level, the hippocampal IDO1 expression was mediated through IL-6 and its downstream JAK/STAT signaling pathway, which in turn altered the kynurenine/tryptophan and serotonin/tryptophan ratios in the hippocampus. The results indicate that brain IDO activity played a critical role in regulating the comorbid interaction between nociceptive and depressive behaviors.

A comorbid relationship between pain and depression has long been recognized in the clinical setting (27, 28). Earlier studies focused on a temporal relationship between pain and depression (e.g., antecedent hypothesis versus consequence hypothesis) (29, 30), but the cellular mechanism underlying this relationship remains unknown. Recent neurobiological studies have suggested...
that both depression and chronic pain may involve the monoamine
ergic system, the hypothalamic/pituitary/adrenal axis, as well as vari-
ous other neurotransmitters/neuromodulators including acet-
ylcholine, GABA, substance P, cholecystokinin, endogenous opioid,
and brain-derived neurotrophic factor (31–35). Despite some pro-
gress, clinical treatment of pain and depression has so far been lim-
lited to symptomatic management (3, 36). A number of studies have
also suggested that the effect of antidepressants on chronic pain is
not necessarily related to their anti-depression property (36–38).

In the present study, the data from human subjects suggests
an apparent relationship between IDO expression/enzyme
activity and clinical symptoms of pain and depression, but this
cross-sectional clinical observation does not explore the causal
relationship between IDO and clinical conditions. On the other
hand, the data from animal experiments suggest a novel mecha-
nistic link between pain and depression via a critical role of IDO1
in the hippocampus. Regulation of hippocampal IDO1 is likely
mediated through an IL-6 signal transduction pathway, because
(a) upregulation of IL-6 as well as downstream JAK and STAT3
preceded the IDO expression in rats with combined nociceptive
and depressive behavior; (b) the hippocampal Il6 mRNA level was
elevated in Id01 gene knockout mice in response to inflammatory
arthritis; (c) inhibition of IDO1 activity by systemic 1-MT treat-
ment did not prevent elevation of the plasma IL-6 level in rats with
both nociceptive and depressive behavior (data not shown); and
(d) IL-6 directly upregulated IDO1 expression in both Neuro2a
cells and an organotypic hippocampal tissue culture. Our data also
indicate that the hippocampus is a critical brain region of IDO
regulation, because IDO1 was selectively upregulated in the hip-
 pocampus, but not in the thalamus or nucleus accumbens. These
findings are consistent with the previous reports that (a) certain
brain regions including the hippocampus play a critical role in
the integration of mood changes and pain (31, 39, 40) and (b) the hip-
 pocampus is related to nociceptive perception and its exacerbation
by mood disorders such as anxiety (41, 42).

Kynurenine and serotonin are two major tryptophan metabo-
lites produced via enzymatic regulation including IDO, which have
been implicated in the mechanisms of pain and depression (4, 5).
Our data indicate that both kynurenine/tryptophan and serotonin/
tryptophan ratios in the hippocampus were closely regulated
by IDO1 activity. This regulatory mechanism appears to have two
important functional implications: on the one hand, increased
IDO activity lowers the endogenous serotonin level (43), which
leads to depression (44) and diminishes the descending inhibition
of pain modulation (45, 46); on the other hand, increased IDO
activity increases kynurenine derivatives such as quinolinic acid,
contributing to neurotoxicity and nociception via the interaction
with glutamate receptors (47). Therefore, IDO is situated in a key
tryptophan metabolic pathway, and alteration of IDO activity
results in changes in the content of endogenous kynurenine and
serotonin, both of which play a critical role in the mechanisms
of pain and depression (Supplemental Figure 2). This notion is
supported by our data showing that concurrent improvement of
pain and depression was achieved by inhibiting IDO1 activity or
IDO gene knockout, which normalized the increased kynurenine/
tryptophan ratio and decreased the serotonin/tryptophan ratio
resulting from hippocampal IDO upregulation. It would be of
interest in future studies to examine the relationship between IDO
expression and other products of tryptophan metabolism and its
role in pain and depression.

Studies in the immunology field have consistently shown a rela-
tionship between inflammatory mediators and IDO expression
in immune cells (48, 49). Studies using central administration
cytoxins have indicated a role for cytokines in various behav-
ioral manifestations. For example, intracerebroventricular (i.c.v.)
administration of IL-6 or IL-1β elicited hyperalgesia (50), as well
as fever, anorexia, and reduction of social exploratory behavior (51,
52). Three recent studies including ours have shown that periph-
eral nerve injury induced depressive behavior in rats (53–55),
which is associated with an increased IL-1β expression in the fron-
tal cortex (54). The present data demonstrate a direct link between
cytokine signaling and IDO expression in the hippocampus. Given
that IDO changes were also demonstrated in a rat model of anhe-
donia, regulation of brain IDO expression may have a broad impli-
cation in the interaction between pain and depression. It will be
of considerable interest in future studies to determine whether a
similar cytokine and IDO link would be relevant to other pain con-
ditions such as neuropathic pain.

The present study supports a central (hippocampal) effect of
IL-6–mediated IDO activity on the behavioral interaction between
pain and depression. First, intra-hippocampal microinjection of
the IDO1 inhibitor 1-MT attenuated both nociceptive and depres-
sive behavior similar to that after systemic 1-MT administration.
Second, neither systemic 1-MT nor intra-hippocampal administra-
tion of IL-6, IL-6 antisera, or 1-MT changed signs of hind paw
inflammation (e.g., redness, swelling), suggesting that the effect
of 1-MT on nociceptive and depressive behavior is unlikely to be
mediated through a peripheral mechanism at the site of hind paw
arthritis. Third, the plasma IDO activity, reflected by an increased
kynurenine/tryptophan ratio, was only transiently increased
on day 1 but not day 7 and 14 after hind paw inflammation.
Fourth, exogenous IL-6 directly upregulated IDO1 expression
and enhanced IDO activity in Neuro2a cells and an organotypic
hippocampal tissue culture. Fifth, intra-hippocampal microinjec-
tion of IL-6 in naive rats induced hippocampal IDO upregulation
as well as nociceptive and depressive behavior, which was blocked
by AG490 (a JAK/STAT inhibitor). Thus, converging evidence from
immunology literature and the current study suggests an impor-
tant role of IDO activity in the central nervous system in addition
to its critical role in immunoregulation (56).

Clinical studies have demonstrated that the plasma IL-6 level
was increased in patients with painful neuropathy, cancer, inflam-
mation (57, 58), and depression (59, 60). In this study, the plasma
IL-6 and IDO level, as well as IDO enzyme activity, was increased
in patients with chronic back pain and depression, consistent
with the findings from animal studies. This raises the possibility
that concurrent treatment of both pain and depression might be
possible through regulation of brain IDO activity, in contrast to
the current approach of symptomatic management using anti-
depressants and analgesics (3). Although the neural and cellular
mechanism underlying the interaction between pain and depres-
sion is likely to be complex and involves other neurotransmitters
and neuromodulators (25–33), the present findings may suggest
a new strategy of clinical intervention. This new strategy focuses
on both prevention and reversal of comorbid interactions between
pain and depression by targeting its underlying mechanism involv-
ing altered ratios of endogenous tryptophan metabolites resulting
from upregulated IDO expression in certain brain regions. Since
IDO inhibitors have been tried in clinical studies of depression
and cancer treatment (61–63), it will be of considerable interest
to examine whether using IDO inhibitor, alone or in combination with other agents blocking IDO upregulation or regulating tryptophan metabolism, would be able to achieve concurrent alleviation of pain and depression in the clinical setting.

Methods

Human subjects
Male and female subjects between 18 and 65 years old were recruited. A total of 33 subjects were recruited from the greater Boston area. Inclusion criteria included (a) chronic lumbar or cervical radicular pain due to disk herniation or radiculitis for at least 3 months; (b) clinical depression without hospitalization within the past 12 months or medication changes; (c) no history of drug abuse confirmed by a negative urine drug screen; (d) no other psychiatric disorders, including schizophrenia, bipolar disorder, and eating disorders; and (e) for normal control subjects, no pain or depression for at least the past 6 months. Board-certified physicians on the research team reviewed and confirmed clinical diagnosis of pain and depression. Blood samples were taken once and used for HPLC and ELISA assays. Of note, the data from human subjects was obtained in a cross-section observational setting, which could be confounded by potential clinical variations such as body weight and a subject’s underlying pain condition as well as a small sample size.

Experimental animals
Male Wistar rats (250–300 g; Charles River) or 7- to 10-week-old male B6.129-Ido1tm1Alm/J (IDO–/–) and C57BL/6J wild-type mice (Jackson Laboratory) were used. Animals were housed individually (21 ± 2°C, relative humidity 50% ± 10%, 12-hour light/12-hour dark cycle), with water and food available ad libitum.

Surgical procedures
Hind paw monoarthritis. Hind paw monoarthritis was induced by the injection of CFA (50 μl) into a unilateral tibiotarsal joint cavity under brief isoflurane anesthesia (13). Animals in sham groups were injected with 50 μl incomplete Freund’s adjuvant. Local redness and joint swelling were observed in CFA-injected rats but not control rats during the experimental period.

Brain cannula implantation and drug injection. Under brief isoflurane anesthesia, a guide cannula (26 gauge, Plastics One) was implanted just above the hippocampus (anteroposterior [AP]: –3.6 mm; left: +2.0 mm from bregma; depth: –4.0 mm from skin) (64). An injection needle (33 gauge, Plastics One) was inserted through the guide cannula, and drug solution or vehicle (0.5 μl) was slowly injected over 5 minutes using a Hamilton syringe. Locations of the cannula placement were confirmed at the time of tissue harvest (Supplemental Figure 3A).

Anhedonia induced by chronic social stress
To induce anhedonia-like behavior in rats, chronic social stress was introduced using a modified resident-intruder social interaction method as described previously (65–67). An experimental rat (275–300 g), designated as an intruder rat in this model, was transferred from its home cage into a cage of a resident rat (500–600 g) for 1 hour per day. The intruder rat and the resident rat were separated by a small, round wire-mesh compartment (diameter 11 cm, height 14 cm) within the resident cage. After 1 hour, the intruder rat was returned to its home cage. This procedure was carried out at the beginning of the dark cycle in a 24-hour light cycle (light on and off for each 12-hour period). An intruder rat was confronted with a different resident rat each day. This process lasted for 4 weeks. For controls, rats were placed in the same behavioral room but without the social interaction with a resident rat.

Behavioral tests
Noxious test. Animals were habituated to a test setting (30-minute session) for 3 consecutive days. Thermal withdrawal threshold was assessed using the Hargreaves apparatus and method (68). Mechanical withdrawal threshold was assessed using von Frey filaments (69).

FST. FST was performed according to the method of Porsolt et al. (14). The total duration of immobility (non-swimming) within a 5-minute session was recorded as immobility scores (in seconds) and compared among groups.

TST. TST was carried out as described previously (70). Briefly, a rat was hung on a hook, using adhesive tape placed 20 mm from the tip of its tail, on a 50-cm-height rod. The immobility time during a 6-minute period of tail suspension was recorded with a stopwatch.

OFT. OFT was carried out in a Plexiglas square box (57 × 57 cm) with walls 50 cm in height (71). Behaviors were observed for 10 minutes under a dim light. After the first 5 minutes (habituation), the number of squares crossed by a rat was recorded for the next 5 minutes.

Sucrose preference test. A sucrose preference test (SPT) was performed as described in previous studies (72, 73). To perform this test, 1% sucrose solution was offered once weekly in a rat’s home cage. Each rat had a free choice between 1% sucrose solution bottle and a tap water bottle. Sucrose and tap water intakes were separately measured by weighing each bottle before and after the test (a 24-hour period). The sum of tap water and sucrose water intake (in grams) was calculated as the total water intake. The sucrose preference was expressed as the percentage of sucrose water intake relative to the total water intake.

Rotarod test. A rotarod test, using an accelerating rotarod apparatus (Columbus Instruments), was performed in both arthritic and sham control rats. Rats were given 3 training sessions and then placed on a 9-cm-diameter rod with speed increased from 0.5 to 30 rpm over a 60-second period. Each rat was tested in 3 consecutive trials with 15-minute intervals. The duration of time on the rotarod was determined automatically by a timer that recorded to the nearest second.

Cultures
Neuro2a cell culture. Neuro2a cells were cultured in Eagle’s minimal essential medium (Invitrogen) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen) in a humidified atmosphere of 5% CO2 and 95% air at 37°C. Cells were treated with 0.5 ng/ml IL-6 or vehicle and collected 24 hours later for assays (74).

Organotypic hippocampal tissue culture. According to a modified method (75, 76), organotypic hippocampal cultures were prepared using hippocampus slices from 5- to 8-day-old Wistar rats. Rat pups were euthanized by decapitation, brains were rapidly removed, and the hippocampus was separated from the brain. Hippocampal slices (350 μm in thickness) were made using a McIlwain tissue chopper (Campden Instruments Ltd.) and placed in Gey’s balanced salt solution (Sigma-Aldrich) with 2 mg/ml t-glucose. Slices were then placed on 30-mm Millicell-CM (Millipore) porous (0.4 μm) membranes. These membranes were transferred into 6-well culture plates filled with an incubation medium (1 ml) consisting of 50% vol/vol minimal essential medium, 25% heat-inactivated horse serum, and 25% HBSS (Invitrogen), supplemented with 25 mM t-glucose. Plates were incubated in a humidified atmosphere of 5% CO2 and 95% air at 37°C. Culture medium was changed 3 times a week. Slices were treated with 100 ng/ml IL-6 or vehicle and collected 24 hours later for assays (77).

Immunohistochemistry
Rats were anesthetized with pentobarbital (50 mg/kg, intraperitoneally) and perfused transcardially with cold 0.9% saline (pH 7.4 ± 0.1), followed by cold 4% paraformaldehyde in a phosphate buffer (PB; 0.1 M,
research article

pH 7.4 ± 0.1). Brains were removed and placed in the same fixative for post-fixation at 4°C for 6 hours. For cryoprotection, the samples were kept with cold 30% sucrose in PBS at 4°C until samples sank to the bottom. Coronal brain sections (30 μm) were cut using a cryostat and then floated in PBS. Sections were blocked with 5% normal donkey serum in 0.3% Triton X-100/PBS for 1 hour at room temperature. Free-floating sections were incubated overnight at 4°C on a rocker with one of the following primary antibodies: 1:100 IDO1 rabbit polyclonal (Santa Cruz Biotechnology Inc.); 1:1,000 NeuN mouse monoclonal (Chemicon); 1:1,000 GFAP mouse monoclonal (BD Biosciences—Pharmingen); 1:1,000 Iba-1 mouse monoclonal (Abcam). Sections were then washed with PBS 3 times and incubated with 1:300 FITC- or cyanine 3–conjugated secondary antibody (Jackson ImmunoResearch Laboratories Inc.) for 1 hour at room temperature. Blue fluorescent DAPI (1:300; Invitrogen) was used to stain the nucleus of fixed, cultured Neuro2A cells for 15 minutes.

Colocalization was examined by adding a second primary antibody following the same procedure as described above. Controls were performed by either omitting primary antibody or using antigen absorption (Supplementary Figure 3B). Images were examined with a fluorescence microscope (Olympus) and captured with a digital camera. The images were analyzed using Adobe Photoshop (version 7).

Western blot analysis
Rats were sacrificed under pentobarbital anesthesia. The hippocampus was separated from the brain and immediately stored on dry ice and kept at −80°C until use. Samples were homogenized in a lysis buffer with SDS containing a cocktail of proteinase inhibitors (Roche). Samples were separated on an SDS-PAGE gel (4%–15% gradient gel; Bio-Rad) and transferred to PVDF membranes (Millipore). Membranes were blocked with 5% nonfat dried milk for 1 hour at room temperature and incubated overnight at 4°C on a rocker with one of following primary antibodies: 1:200 IDO1 (Santa Cruz Biotechnology Inc.; rabbit polyclonal antibody), 1:200 IDO1 (Novus Biologicals; rabbit polyclonal antibody), 1:500 JAK2 (Santa Cruz Biotechnology Inc.; rabbit polyclonal antibody), 1:1,000 STAT3 (Millipore; rabbit polyclonal antibody), 1:5,000 p-STAT3 (Abcam; rabbit monoclonal antibody). After membranes were washed with PBS 4 times, membranes were incubated with 1:8,000 HRP-conjugated secondary antibody (Amersham Biosciences, GE Healthcare) for 1 hour at room temperature on a rocker. The membranes were washed with PBS 4 times, and blots were visualized in enhanced chemiluminescent (ECL) solution (Pierce) for 5 minutes and exposed to hyperfilms (Kodak) for 15 minutes. Blots were again incubated in a stripping buffer (Pierce) for 15 minutes at room temperature on a rocker and reprobed with 1:12,000 anti–β-actin antibody (Abcam Inc.) as a loading control. Western blots were made in triplicate. Band density was measured and normalized against a loading control band.

ELISA
Under pentobarbital anesthesia, whole blood was collected from the left ventricle of the heart and placed in a serum collection tube (BD Vacutainer). Blood clots were formed after 30–60 minutes at room temperature, and the tube was centrifuged for 10 minutes at 9,659.52 g. An ELISA Quantikine kit (R&D Systems) and IDO ELISA kit (TSZ ELISA) were used according to the manufacturers’ instructions. Optical density of samples was read at wavelengths of 450 and 570 nm using a microplate reader (Synergy HT, BioTEK). A standard curve, provided by the manufacturer, was generated for each set of samples assayed, and the concentration of each sample was obtained according to the standard curve.

Real-time RT-PCR
Total RNA was isolated from hippocampal samples using TRIzol reagent (Invitrogen). Four micrograms of total RNA was used to synthesize the first-strand cDNA using a SuperScript III kit (Invitrogen). Four microliters of cDNA was put into a 20-μl vessel using 1 μl of x20 TaqMan Gene Expression Assay. TaqMan Gene Expression Assays (Applied Biosystems) containing primers and a TaqMan probe were used to quantify each gene of interest. The genes examined were Il6 (Rn01410330 m1, M207644.1) and Ido1 (Rn00576778 m1, AF132899.1) for rats and Il6 (Mm0046190 m1, X54521) and Ido1 (Mm00492586 m1, M69109.1) for mice. The reaction was performed in duplicate with the following conditions: denaturing at 95°C for 30 seconds, annealing at 60°C for 2 minutes, extension at 68°C for 2 minutes for 40 cycles using a 7300 Real-Time PCR System (Applied Biosystems). The RNA expression of GAPDH was measured as control.

HPLC
Hippocampal tryptophan, kynurenine, and serotonin content was determined by HPLC (78, 79). All samples were taken between 2 and 5 p.m. Kynurenine was measured by a UV detector (Shimadzu, SPD-10Avp; 360-nm wavelength). Tryptophan and serotonin were measured by a fluorescence detector (Shimadzu, RF-10Axl; 286-nm excitation and 366-nm emission wavelengths). Each day, external calibration was made by using freshly prepared control samples of the same concentrations (100 nmol/l tryptophan, 100 μmol/l kynurenine, and 100 nmol/l serotonin).

Statistics
Repeated measures 2-way ANOVA was used and followed by the Tukey test to detect interactions between test time points and groups. Correlations between nociceptive and depressive behavior were determined using Pearson correlation coefficient analysis. HPLC, Western blot, and ELISA data were analyzed using 1-way ANOVA followed by a Tukey or Dunn test. Statistical analyses were performed using SigmaStat (Systat, version 11), with a significance level of P < 0.05.

Study approval
Informed consent was obtained from study participants. Research protocols were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. Experiments were conducted with the experimenter being unaware of the group assignment.

Acknowledgments
This study was supported by NIH grants R01DE18214, R01DE18538, and P20DA26002 (to J. Mao).

Received for publication November 11, 2011, and accepted in revised form May 16, 2012.

Address correspondence to: Jianren Mao, MGH Center for Translational Pain Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. Phone: 617.726.2338; Fax: 617.724.2719; E-mail: jmao@partners.org.


